Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription Articles published in Acta Haematol Retrieve available abstracts of 83 articles: HTML format

Single Articles

August 2025
1. LEVY YURKOVSKI I, Tadmor T
   Approach to hairy-cell leukemia in the new therapeutic era with special emphasis on age and comorbidities.
   Acta Haematol. 2025 Aug 4:1-19. doi: 10.1159/000547722.
   PubMed     Abstract available
   
   
   July 2025
2. SENAPATI J, Short NJ
   Advances in Acute Lymphoblastic Leukemia Review Series.
   Acta Haematol. 2025 Jul 29:1-5. doi: 10.1159/000547659.
   PubMed    
   
   
   
3. RAFAELI N, Kebriaei P
   Future Directions in Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia.
   Acta Haematol. 2025 Jul 25:1-12. doi: 10.1159/000547644.
   PubMed     Abstract available
   
   
   
4. SABILE JM, Zhang P, Parwani AV, Chobrutskiy B, et al
   Towards Clinically Actionable Machine Learning and Artificial Intelligence Algorithms in Acute Leukemia: A Systematic Narrative Review.
   Acta Haematol. 2025 Jul 24:1-25. doi: 10.1159/000547532.
   PubMed     Abstract available
   
   
   
5. MUNIR T, Ciburiene E, Graklanov V, Gospodinova M, et al
   Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists.
   Acta Haematol. 2025 Jul 18:1-24. doi: 10.1159/000547426.
   PubMed     Abstract available
   
   
   
6. ZHANG L, Zhang Z, Lu A, Jia Y, et al
   Venetoclax-based regimen in refractory or relapsed pediatric acute lymphoblastic leukemia.
   Acta Haematol. 2025 Jul 8:1-18. doi: 10.1159/000547080.
   PubMed     Abstract available
   
   
   June 2025
7. TORRENT A, Ribera JM
   Treatment of Philadelphia positive acute lymphoblastic leukemia.
   Acta Haematol. 2025 Jun 24:1-22. doi: 10.1159/000547026.
   PubMed     Abstract available
   
   
   
8. MENDEZ LM, DeAngelo DJ, Luskin MR
   Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
   Acta Haematol. 2025 Jun 10:1-22. doi: 10.1159/000546381.
   PubMed     Abstract available
   
   
   May 2025
9. MCCALL D, Catueno S, Ramakrishnan R, Tewari P, et al
   Beyond Cellular Therapies: The Expanding Role of Antibody-Driven Immunotherapy in Pediatric Acute Lymphoblastic Leukemia.
   Acta Haematol. 2025 May 5:1-31. doi: 10.1159/000546249.
   PubMed     Abstract available
   
   
   
10. LE COUTRE P, Burchert A, Saussele S, Schwarzer T, et al
    Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generatio
    Acta Haematol. 2025 May 5:1-13. doi: 10.1159/000545826.
    PubMed     Abstract available
    
    
    April 2025
11. SHERBAN A, Frisch A, Rozental A, Buchrits S, et al
    Epiglottitis in Patients Treated for Acute Leukemia - Case Series and Systematic Review of the Literature.
    Acta Haematol. 2025 Apr 17:1-21. doi: 10.1159/000545927.
    PubMed     Abstract available
    
    
    
12. YAO X, Wang H, Yang L
    Global, regional, and national burden of leukemia, 1990-2021: a systematic analysis for the global burden of disease study 2021.
    Acta Haematol. 2025 Apr 14:1-27. doi: 10.1159/000545724.
    PubMed     Abstract available
    
    
    
13. ZEIDAN AM, Yu R, Wang Y, Lan Z, et al
    STREAMLINE - Retrospective Cohort Study of FMS-like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia: Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis.
    Acta Haematol. 2025 Apr 14:1-20. doi: 10.1159/000545384.
    PubMed     Abstract available
    
    
    
14. GILBERT JS, Pollyea DA, Walsh TJ, Groll AH, et al
    Recombinant myeloid hematopoietic growth factors and clinical stimulation of acute myeloid leukemia cells: a narrative review.
    Acta Haematol. 2025 Apr 8:1-15. doi: 10.1159/000545588.
    PubMed     Abstract available
    
    
    March 2025
15. NANDURI AC, Ashraf F, Hlaing SS, Brister M, et al
    Acute Promyelocytic Leukemia Presenting with Cranial Nerve Involvement and Clivus Mass.
    Acta Haematol. 2025 Mar 29:1-15. doi: 10.1159/000545444.
    PubMed     Abstract available
    
    
    
16. SHAPIRA S, Mizrahi B, Hirschberger N, Rabinowicz N, et al
    Mind-Body Intervention in Chronic Lymphocytic Leukemia During the Watch-and-Wait Phase: Benefits Linked to Intervention Duration.
    Acta Haematol. 2025 Mar 24:1-6. doi: 10.1159/000545407.
    PubMed     Abstract available
    
    
    
17. SEYITHANOGLU D, Sert EN, Ozbalak M, Mastanzade M, et al
    The Effect of T-Lymphocyte Subgroups at Diagnosis on The Prognosis of Chronic Lymphocytic Leukemia.
    Acta Haematol. 2025 Mar 17:1-11. doi: 10.1159/000545269.
    PubMed     Abstract available
    
    
    
18. MCCALL D, Karol SE, Short NJ
    The Need for Concurrent Chemoimmunotherapy in Pediatric B-Cell Lymphoblastic Leukemia.
    Acta Haematol. 2025 Mar 7:1-7. doi: 10.1159/000545028.
    PubMed    
    
    
    January 2025
19. OANUNU U, Gross Even Zohar N, Aumann S, Vainstein V, et al
    Prognostic Factors, FLT-3 Mutations, and Treatment Outcomes with pediatric inspired protocols in adolescent and young adults (AYA) and adult patients with Acute Lymphoblastic Leukemia.
    Acta Haematol. 2025 Jan 30:1-24. doi: 10.1159/000543861.
    PubMed     Abstract available
    
    
    
20. LV W, Wang Y, Hu F, Huang H, et al
    A prognostic survival model based on endocrine-related gene expression in acute myelogenous leukemia.
    Acta Haematol. 2025 Jan 14:1-21. doi: 10.1159/000543272.
    PubMed     Abstract available
    
    
    
21. CHO HJ, Baek DW, Kim J, Jang YE, et al
    Real-World Experience in the Management of Chronic Myeloid Leukemia Patients Focused on Tyrosine Kinase Inhibitors Intolerance and Health-Related Quality of Life.
    Acta Haematol. 2025 Jan 10:1-14. doi: 10.1159/000542562.
    PubMed     Abstract available
    
    
    
22. ROEKER LE, Coombs CC, Shah NN, Jurczak W, et al
    Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies.
    Acta Haematol. 2025;148:180-197.
    PubMed     Abstract available
    
    
    
23. BRUNO DS, Khanal M, Li XI, Escalon MP, et al
    Racial and Ethnic Characteristics and Outcomes of Patients Diagnosed with CLL/SLL in the USA.
    Acta Haematol. 2025;148:148-162.
    PubMed     Abstract available
    
    
    
24. DRAGOI OD, Shah M, Potter V, Avenoso D, et al
    Disseminated Mucormycosis and T-Cell-Depleted Allogeneic Stem Cell Transplantation: An Unusual Case Study.
    Acta Haematol. 2025;148:362-368.
    PubMed     Abstract available
    
    
    
25. SANCHEZ-PETITTO G, Goloubeva O, Childress J, Iqbal T, et al
    Outcomes of Patients with Myeloid Malignancies and Cardiovascular Disease Undergoing Allogeneic Stem Cell Transplantation.
    Acta Haematol. 2025;148:386-397.
    PubMed     Abstract available
    
    
    December 2024
26. DAUNGSUPAWONG H, Wiwanitkit V
    Haploidentical allogeneic hematopoietic cell transplantation following two courses of venetoclax and azacytidine therapy in patients over 55 years old with acute myelogenous leukemia: Comment.
    Acta Haematol. 2024 Dec 2:1-3. doi: 10.1159/000542843.
    PubMed    
    
    
    October 2024
27. KONG J, Miao W, Lu J, Liu Y, et al
    Shorter duration of Blinatumomab administration to 14 days has same efficacy and safety profile in treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A retrospective single-center study.
    Acta Haematol. 2024 Oct 28:1-10. doi: 10.1159/000542060.
    PubMed     Abstract available
    
    
    
28. CAO J, Zhuang X, Luo D, Pei R, et al
    Efficacy of haploidentical allogeneic hematopoietic cell transplantation following two courses of venetoclax and azacytidine therapy in patients over 55 years old with acute myelogenous leukemia.
    Acta Haematol. 2024 Oct 25:1-18. doi: 10.1159/000542034.
    PubMed     Abstract available
    
    
    
29. LIANG Q, Liu Z, Wu Y, Zhu H, et al
    Sudden Blast Crisis in a chronic myeloid leukemia patient in Treatment Free Remission: A case report and literature review.
    Acta Haematol. 2024 Oct 21:1-16. doi: 10.1159/000542153.
    PubMed     Abstract available
    
    
    September 2024
30. TADMOR T, Melamed G, Alapi H, Gazit S, et al
    Intake of Proton Pump Inhibitors is Associated with a Shorter Time To First Treatment in early-stage Chronic Lymphocytic Leukemia.
    Acta Haematol. 2024 Sep 30:1-9. doi: 10.1159/000541453.
    PubMed     Abstract available
    
    
    
31. IURLO A, Bucelli C, Intermesoli T, Elena C, et al
    BOSUTINIB TREATMENT OF CHRONIC MYELOID LEUKEMIA IN LOMBARDY.
    Acta Haematol. 2024 Sep 18:1-13. doi: 10.1159/000540572.
    PubMed     Abstract available
    
    
    June 2024
32. NIEHUS HD, Sabile J, Maziarz RT, Meyers G, et al
    Enhanced Survival of Chronic Myelomonocytic Leukemia (CMML)-Dysplastic over Proliferative Subtype After Allogeneic Hematopoietic Cell Transplant: A Tertiary Center Experience and Literature Review.
    Acta Haematol. 2024 Jun 26. doi: 10.1159/000539880.
    PubMed     Abstract available
    
    
    
33. MARVIN-PEEK J, Shelton V, Brassil K, Fellman B, et al
    Effect of Digital Health Coaching on Self-Efficacy and Patient Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia: A Pilot Randomized Controlled Trial.
    Acta Haematol. 2024 Jun 11. doi: 10.1159/000539756.
    PubMed     Abstract available
    
    
    May 2024
34. LIU Y, Ning Y, Ghiaur G, Emadi A, et al
    Biologic and clinical characteristics of isochromosome der(17)(q10)t(15;17) in acute promyelocytic leukemia.
    Acta Haematol. 2024 May 31. doi: 10.1159/000539159.
    PubMed     Abstract available
    
    
    
35. ZENG X, Liu K, Xu R, Zhang L, et al
    TES and SLC40A1 as potential biomarkers for predicting survival in T-cell acute lymphoblastic leukemia.
    Acta Haematol. 2024 May 28. doi: 10.1159/000539435.
    PubMed     Abstract available
    
    
    
36. DAMPMANN M, Flossdorf S, Keyl J, Reinhardt HC, et al
    Single-center experience of patients with plasma cell leukemia in the era of new therapeutics.
    Acta Haematol. 2024 May 19. doi: 10.1159/000539223.
    PubMed     Abstract available
    
    
    April 2024
37. JIN X, Jiang X, Li H, Shen K, et al
    Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.
    Acta Haematol. 2024 Apr 16. doi: 10.1159/000538658.
    PubMed     Abstract available
    
    
    
38. NASNAS PE, Jabbour EJ, Sasaki K, Issa GC, et al
    Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia.
    Acta Haematol. 2024 Apr 4. doi: 10.1159/000538651.
    PubMed     Abstract available
    
    
    March 2024
39. PAN L, Zheng Y, Zheng H
    Long Non-coding RNA RP11-252C15.1 is a Potential Biomarker of Prognosis and Hallmark for Leukemogenesis in Children with B-cell Precursor Acute Lymphoblastic Leukemia.
    Acta Haematol. 2024 Mar 25. doi: 10.1159/000535461.
    PubMed     Abstract available
    
    
    
40. BENJAMINI O, Tadmor T, Avigdor A, Gershon R, et al
    Efficacy of preexposure prophylaxis with monoclonal-antibody tixagevimab-cilgavimab against emerging SARS-CoV-2 resistant variants in patients with chronic lymphocytic leukemia.
    Acta Haematol. 2024 Mar 12. doi: 10.1159/000537690.
    PubMed     Abstract available
    
    
    
41. SHAPIRA S, Hirschberger N, Ofran Y, Mizrahi B, et al
    The effect of mind-body intervention on lymphocyte doubling time and treatment free survival in treatment-naive chronic lymphocytic leukemia patients.
    Acta Haematol. 2024 Mar 8. doi: 10.1159/000538055.
    PubMed     Abstract available
    
    
    
42. MORIGUCHI M, Ido K, Okamura H, Nakamae M, et al
    Impacts of Posttransplant Cyclophosphamide Dose on Graft-versus-leukemia Effects via HLA-B Leader in HLA-haploidentical Peripheral Blood Stem Cell Transplantation.
    Acta Haematol. 2024 Mar 1. doi: 10.1159/000538078.
    PubMed     Abstract available
    
    
    February 2024
43. PARIGGER T, Drothler S, Scherhaufl C, Gassner FJ, et al
    Oncogenic MTOR signaling axis compensates BTK inhibition in a Chronic Lymphocytic Leukemia patient with Richter Transformation: A Case Report and Review of the Literature.
    Acta Haematol. 2024 Feb 24. doi: 10.1159/000537791.
    PubMed     Abstract available
    
    
    
44. LACHAINE J, Beauchemin C, Dodat F, Au Y, et al
    Evaluating the economic burden of acute myeloid leukemia in Canada.
    Acta Haematol. 2024 Feb 21. doi: 10.1159/000537725.
    PubMed     Abstract available
    
    
    
45. ZHANG Q, Dong Y, Zhai Z, Tao L, et al
    Lenalidomide treatment of isolated central nervous system relapse in acute lymphoblastic leukemia after HSCT and CAR-T cell therapy.
    Acta Haematol. 2024 Feb 15. doi: 10.1159/000537719.
    PubMed     Abstract available
    
    
    
46. ZHONG T, Xu D, Li W
    Prevalence, risk factors, and prognostic value of anxiety and depression in acute myeloid leukemia.
    Acta Haematol. 2024 Feb 11. doi: 10.1159/000536457.
    PubMed     Abstract available
    
    
    January 2024
47. HU GH, Zhang XH, Liu KY, Xu LP, et al
    Outcome and prognostic factors of haploidentical allogeneic hematopoietic stem cell transplantation in pediatric relapsed or refractory ETV6/RUNX1-positive acute lymphoblastic leukemia.
    Acta Haematol. 2024 Jan 20. doi: 10.1159/000536396.
    PubMed     Abstract available
    
    
    
48. WACHTER F, Pikman Y
    Pathophysiology of Acute Myeloid Leukemia (AML).
    Acta Haematol. 2024 Jan 16. doi: 10.1159/000536152.
    PubMed     Abstract available
    
    
    
49. TROUSSARD X
    Unusual clinical presentations of hairy cell leukemia.
    Acta Haematol. 2024 Jan 4. doi: 10.1159/000536043.
    PubMed    
    
    
    
50. AL-SAWAF O
    Importance of Minimal Residual Disease in the Era of Targeted Therapies in Chronic Lymphocytic Leukemia.
    Acta Haematol. 2024;147:22-32.
    PubMed     Abstract available
    
    
    
51. TADMOR T, Burger J
    Chronic Lymphocytic Leukemia: Novel Perspectives - How to Teach an Old Dog New Tricks.
    Acta Haematol. 2024;147:5-7.
    PubMed    
    
    
    
52. KANG S, Ahn IE
    Prognostic Markers in the Era of Targeted Therapies.
    Acta Haematol. 2024;147:33-46.
    PubMed     Abstract available
    
    
    
53. GARGIULO E, Teglgaard RS, Faitova T, Niemann CU, et al
    Immune Dysfunction and Infection - Interaction between CLL and Treatment: A Reflection on Current Treatment Paradigms and Unmet Needs.
    Acta Haematol. 2024;147:84-98.
    PubMed     Abstract available
    
    
    
54. CARLSON KS, Cunningham A, Stahl M, Winer E, et al
    Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems?
    Acta Haematol. 2024;147:122-132.
    PubMed     Abstract available
    
    
    
55. JIMENEZ-CHILLON C, Dillon R, Russell N
    Optimal Post-Remission Consolidation Therapy in Patients with AML.
    Acta Haematol. 2024;147:147-158.
    PubMed     Abstract available
    
    
    
56. BUCHRITS S, Wolach O
    Non-Immunotherapy Approaches for Relapsed or Refractory AML: An Update for 2024.
    Acta Haematol. 2024;147:159-174.
    PubMed     Abstract available
    
    
    
57. MOLICA S, Rossi M, Allsup D
    Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide.
    Acta Haematol. 2024;147:257-259.
    PubMed     Abstract available
    
    
    December 2023
58. DIGENNARO J, Sallman DA
    TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies and Future Considerations.
    Acta Haematol. 2023 Dec 5. doi: 10.1159/000535628.
    PubMed     Abstract available
    
    
    November 2023
59. WOODS JD, Klepin HD
    Geriatric assessment in Acute Myeloid Leukemia (AML).
    Acta Haematol. 2023 Nov 30. doi: 10.1159/000535500.
    PubMed     Abstract available
    
    
    
60. SHIMONY S, Stone RM
    Untangling Complexities of Acute Myeloid Leukemia Review Series.
    Acta Haematol. 2023 Nov 30. doi: 10.1159/000535574.
    PubMed    
    
    
    
61. BLACKMON AL, Hourigan CS
    Test then erase? Current status and future opportunities for Measurable Residual Disease testing in Acute Myeloid Leukemia.
    Acta Haematol. 2023 Nov 30. doi: 10.1159/000535463.
    PubMed     Abstract available
    
    
    
62. HOFFMAN T, Atamna A, Litchevsky V, Amitai I, et al
    Fluoroquinolone Prophylaxis During Conventional Chemotherapy or Hematopoietic Stem Cell Transplantation for Acute Leukemia - Pros and Cons.
    Acta Haematol. 2023 Nov 21. doi: 10.1159/000535119.
    PubMed     Abstract available
    
    
    
63. COWEN EA, Barrios DM, Pulitzer MP, Moy AP, et al
    Acute febrile neutrophilic dermatosis (Sweet syndrome) in acute myeloid leukemia patients: a 28-year institutional experience.
    Acta Haematol. 2023 Nov 21. doi: 10.1159/000535399.
    PubMed     Abstract available
    
    
    
64. RIOS-OLAIS FA, Gil-Lopez F, Mora-Canas A, Demichelis-Gomez R, et al
    Tumor lysis syndrome is associated with worse outcomes in adult patients with acute lymphoblastic leukemia.
    Acta Haematol. 2023 Nov 14. doi: 10.1159/000534453.
    PubMed     Abstract available
    
    
    
65. ITO K, Harada K, Uchino Y, Hirano K, et al
    A Rare Clinical Case of Secondary Central Nervous System Involvement without Transformation in Hairy Cell Leukemia: Case Report and Literature Review.
    Acta Haematol. 2023 Nov 10. doi: 10.1159/000535066.
    PubMed     Abstract available
    
    
    
66. ZHAO MN, Su L, Song F, Wei ZF, et al
    Shikonin exerts an anti-leukemia effect against FLT3-ITD mutated acute myeloid leukemia cells via targeting FLT3 tyrosine kinase and its downstream pathways.
    Acta Haematol. 2023 Nov 3. doi: 10.1159/000534101.
    PubMed     Abstract available
    
    
    October 2023
67. ARGUELLO-TOMAS M, Albiol N, Moreno C
    Frontline therapy in Chronic Lymphocytic Leukemia.
    Acta Haematol. 2023 Oct 27. doi: 10.1159/000534730.
    PubMed     Abstract available
    
    
    
68. SAUSSELE S, La Rosee P, Kiani A, Haverkamp W, et al
    Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia.
    Acta Haematol. 2023 Oct 17. doi: 10.1159/000533666.
    PubMed     Abstract available
    
    
    
69. MINCULESCU L, Reekie J, Petersen SL, Kornblit BT, et al
    Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation.
    Acta Haematol. 2023 Oct 12. doi: 10.1159/000534315.
    PubMed     Abstract available
    
    
    
70. HAREL R, Itchaki G
    COVID-19 in Patients with Chronic Lymphocytic Leukemia - What Have We Learned?
    Acta Haematol. 2023 Oct 11. doi: 10.1159/000534540.
    PubMed     Abstract available
    
    
    
71. KATZ OB, Yehudai-Ofir D, Zuckerman T
    Cellular therapy in chronic lymphocytic leukemia: have we advanced in the last decade?
    Acta Haematol. 2023 Oct 9. doi: 10.1159/000534341.
    PubMed     Abstract available
    
    
    
72. BELLO E, Liao H, Patel SA
    Clinico-Radio-Pathologic Correlation of Leukostasis in Acute Myeloid Leukemia with FLT3 Mutation.
    Acta Haematol. 2023 Oct 3. doi: 10.1159/000531832.
    PubMed     Abstract available
    
    
    September 2023
73. ALSHEMMARI SH, A Siddiqui M, Pandita R, Osman HY, et al
    Evidence-based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region.
    Acta Haematol. 2023 Sep 26. doi: 10.1159/000531675.
    PubMed     Abstract available
    
    
    
74. BAE S, Sa S, Park S, Cho BS, et al
    Limited efficacy of Venetoclax Combination Regimens in Acute Myeloid Leukemia with Extramedullary Relapse.
    Acta Haematol. 2023 Sep 26. doi: 10.1159/000534026.
    PubMed     Abstract available
    
    
    
75. SASTOW D, Van Hyfte G, Feld J, Kremyanskaya M, et al
    Exclusion of Acute Myeloid Leukemia Patients with Central Nervous System Involvement from Clinical Trials: An Analysis of the National Institutes of Health Clinical Trials Registry from 2012-2022.
    Acta Haematol. 2023 Sep 26:1. doi: 10.1159/000533819.
    PubMed     Abstract available
    
    
    
76. KOEHRER S, Burger JA
    Chronic lymphocytic leukemia: disease biology.
    Acta Haematol. 2023 Sep 16. doi: 10.1159/000533610.
    PubMed     Abstract available
    
    
    
77. CHEN EC, Garcia JS
    Immunotherapy for acute myeloid leukemia: current trends, challenges, and strategies.
    Acta Haematol. 2023 Sep 6. doi: 10.1159/000533990.
    PubMed     Abstract available
    
    
    
78. LEVY YURKOVSKI I, Tadmor T
    Accelerated Chronic Lymphocytic Leukemia and Richter Transformation in the Era of Novel Agents.
    Acta Haematol. 2023 Sep 4. doi: 10.1159/000533664.
    PubMed     Abstract available
    
    
    January 2023
79. HERSHENFELD SA, Atenafu EG, Chan S, Gupta V, et al
    Impact of Geographical Distance from Quaternary Treatment Center on Clinical Trial Participation, Intensive Induction Chemotherapy, and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Acta Haematol. 2023;146:366-372.
    PubMed     Abstract available
    
    
    
80. BURMEISTER T, Bullinger L, le Coutre P
    The Recurrent Atypical e8a2 BCR::ABL1 Transcript with Insertion of an Inverted 55 Base Pair ABL1 Intron 1b Sequence: A Detailed Molecular Analysis.
    Acta Haematol. 2023;146:413-418.
    PubMed     Abstract available
    
    
    
81. PAPADOPOULOU V, Schoumans J, Scarpelli I, Blum S, et al
    Description of an Institutional Cohort of Myeloid Neoplasms Carrying ETV6-Locus Deletions or ETV6 Rearrangements.
    Acta Haematol. 2023;146:401-407.
    PubMed     Abstract available
    
    
    
82. TINAJERO J, Ngo D, Puing A, Koller P, et al
    Treatment Outcomes of Acute Myeloid Leukemia in Patients Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: A Single-Center Experience.
    Acta Haematol. 2023;146:490-495.
    PubMed     Abstract available
    
    
    
83. TINAJERO J, Ngo D, Salhotra A, Koller P, et al
    Cladribine, Cytarabine, and Etoposide-Based Regimens Are Safe and Tolerable In Relapsed and Refractory Acute Myeloid Leukemia Patients.
    Acta Haematol. 2023;146:538-542.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.